| Primary |
| Product Used For Unknown Indication |
18.4% |
| Drug Use For Unknown Indication |
15.5% |
| Fungal Infection |
7.3% |
| Tinea Pedis |
7.3% |
| Oral Candidiasis |
5.3% |
| Vaginal Infection |
5.3% |
| Vulvovaginal Pruritus |
3.9% |
| Back Pain |
3.4% |
| Vulvovaginal Candidiasis |
3.4% |
| Vulvovaginal Mycotic Infection |
3.4% |
| Atrial Fibrillation |
2.9% |
| Blood Cholesterol Increased |
2.9% |
| Lichen Planus |
2.9% |
| Pain |
2.9% |
| Stress |
2.9% |
| Depression |
2.4% |
| Oral Fungal Infection |
2.4% |
| Pruritus |
2.4% |
| Tinea Cruris |
2.4% |
| Tinea Infection |
2.4% |
|
| International Normalised Ratio Increased |
18.0% |
| Maternal Drugs Affecting Foetus |
10.0% |
| Drug Interaction |
8.0% |
| Anaphylactoid Reaction |
6.0% |
| Maternal Exposure During Pregnancy |
6.0% |
| Off Label Use |
6.0% |
| Hypersensitivity |
5.0% |
| Neural Tube Defect |
5.0% |
| Vulvovaginal Pruritus |
5.0% |
| Anaphylactic Reaction |
4.0% |
| Cervical Polyp |
4.0% |
| Drug Exposure During Pregnancy |
3.0% |
| Dyspnoea |
3.0% |
| Pain In Extremity |
3.0% |
| Skin Haemorrhage |
3.0% |
| Vulvovaginal Erythema |
3.0% |
| Drug Ineffective |
2.0% |
| Penis Disorder |
2.0% |
| Pulmonary Haemorrhage |
2.0% |
| Shock Haemorrhagic |
2.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
13.4% |
| Fungal Infection |
9.7% |
| Product Used For Unknown Indication |
9.2% |
| Tinea Pedis |
8.4% |
| Oral Candidiasis |
7.6% |
| Ill-defined Disorder |
6.3% |
| Depression |
5.5% |
| Vaginal Infection |
5.5% |
| Dyspepsia |
5.0% |
| Asthma |
3.4% |
| Nasopharyngitis |
3.4% |
| Vulvovaginal Pruritus |
3.4% |
| Anxiety |
2.5% |
| Atrial Fibrillation |
2.5% |
| Cellulitis |
2.5% |
| Drug Therapy |
2.5% |
| Pain |
2.5% |
| Vulvovaginitis |
2.5% |
| Oral Fungal Infection |
2.1% |
| Rash |
2.1% |
|
| International Normalised Ratio Increased |
9.0% |
| Pain In Extremity |
9.0% |
| Anaphylactoid Reaction |
7.7% |
| Maternal Exposure During Pregnancy |
7.7% |
| Vomiting |
7.7% |
| Vulvovaginal Erythema |
7.7% |
| Anaphylactic Reaction |
5.1% |
| Cervical Polyp |
5.1% |
| Hypersensitivity |
5.1% |
| Swelling Face |
5.1% |
| Adverse Event |
3.8% |
| Blister |
3.8% |
| Oedema Mouth |
3.8% |
| Skin Haemorrhage |
3.8% |
| Drug Hypersensitivity |
2.6% |
| Drug Interaction |
2.6% |
| Dyspnoea |
2.6% |
| Haematoma |
2.6% |
| Loss Of Consciousness |
2.6% |
| Off Label Use |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
13.4% |
| Product Used For Unknown Indication |
11.8% |
| Prophylaxis |
8.9% |
| Pain |
5.6% |
| Depression |
5.3% |
| Hypertension |
5.0% |
| Infection Prophylaxis |
4.8% |
| Antifungal Prophylaxis |
4.3% |
| Antiviral Prophylaxis |
4.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.0% |
| Pneumonia |
3.8% |
| Diabetes Mellitus |
3.6% |
| Bone Marrow Conditioning Regimen |
3.3% |
| Crohn's Disease |
3.3% |
| Dysmenorrhoea |
3.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.3% |
| Non-small Cell Lung Cancer |
3.1% |
| Type 1 Diabetes Mellitus |
3.1% |
| Cancer Pain |
3.0% |
| Convulsion |
3.0% |
|
| Sepsis |
9.9% |
| Renal Failure Acute |
7.4% |
| Pruritus |
6.2% |
| Rash |
6.2% |
| Vision Blurred |
6.2% |
| White Blood Cell Count Decreased |
6.2% |
| Death |
4.9% |
| Pulmonary Embolism |
4.9% |
| Stevens-johnson Syndrome |
4.9% |
| Stomatitis |
4.9% |
| Thrombocytopenia |
4.9% |
| Toxic Epidermal Necrolysis |
4.9% |
| Weight Decreased |
4.9% |
| Completed Suicide |
3.7% |
| International Normalised Ratio Increased |
3.7% |
| Toxic Skin Eruption |
3.7% |
| Toxicity To Various Agents |
3.7% |
| Urinary Tract Infection |
3.7% |
| Chest Pain |
2.5% |
| Duodenal Ulcer |
2.5% |
|
| Interacting |
| Atrial Fibrillation |
20.0% |
| Mouth Ulceration |
20.0% |
| Oesophageal Ulcer |
20.0% |
| Aphthous Stomatitis |
10.0% |
| Pain |
10.0% |
| Tongue Disorder |
10.0% |
| Type 2 Diabetes Mellitus |
10.0% |
|
| Haematoma |
25.0% |
| Malaise |
25.0% |
| Multi-organ Failure |
25.0% |
| Tongue Ulceration |
25.0% |
|
